One managed care organization is gambling that combining technology and medicine will improve the health of its plan members, and improve its disease management efforts.
One managed care organization is gambling that combining technology and medicine will improve the health of its plan members, and improve its disease management efforts.
Mid Atlantic Medical Services Inc., Rockville, MD, has agreed to supply plan members with congestive heart failure with Medi-Monitors - videotape-sized portable interactive telemedicine devices that encourage them to take medications properly and assess health status and quality of life.
Each device, manufactured by InforMedix, also of Rockville, features a display screen that provides patients with detailed information about their medicines. It retains a month's supply of up to five medications in individual compartments and can be programmed to issue beeps and reminders for additional medications.
"Since medications don't work if you don't take them, the Medi-Monitor helps people take their medications at the right time in the right order, and in the right dosage," said Bruce Kehr, M.D., president of InforMedix and inventor of the product, which was awarded for "Most Effective Use of Cutting-Edge Technology" at the 1998 Congress of the American Medical Informatics Association in June.
The technology monitors medication use and health status by providing a date- and time-stamped record of when the patient took his or her medications. It then electronically transmits the information, along with patient responses to questions about symptoms, side effects and medical status, by telephone via a built-in modem. This helps physicians monitor the condition and progress of patients at home.
Mid Atlantic Medical Services Inc. will recruit plan members with congestive heart failure to participate in the voluntary program for 12 months. The collected data will be made available to the patients' physicians, case managers and consulting pharmacists for review and analysis. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.